Table 1
From: Short and long-term safety of MP29-02*: a new therapy for the treatment of allergic rhinitis
MP4002 SAR study (14 days) | Â | Â | Â | Â |
|---|---|---|---|---|
| Â | MP29-02* (n=207) | FP (n=207) | AZE (n=208) | Placebo (n=210) |
TRAE n (%) | 17 (8.2%) | 14 (6.8%) | 16 (7.7%) | 8 (3.8%) |
Dysgeusia | 5 (2.4%) | 2 (1.0%) | 7 (3.4%) | 1 (0.5%) |
Epistaxis | 2 (1.0%) | 5 (2.4%) | 4 (1.9%) | 2 (1.0%) |
Headache | 1 (0.5%) | 5 (2.4%) | 1 (0.5%) | 3 (1.4%) |
Chronic rhinitis study (52 weeks) | Â | Â | Â | Â |
| Â | MP29-02* (n=404) | FP (n=207) | Â | Â |
TRAE n (%) | 38 (9.4%) | 23 (11.1%) | Â | Â |
Dysgeusia | 10 (2.5%) | 1 (0.5%) | Â | Â |
Epistaxis | 5 (1.2%) | 1 (0.5%) | Â | Â |
Headache | 4 (1.0%) | 9 (4.3%) | Â | Â |